Pulmonary Arterial Hypertension Market size was valued at USD 5.0 billion in 2015 and is anticipated to reach USD 8.7 billion by 2025. Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. These arteries are called pulmonary arteries. PAH occurs when the pulmonary arteries thicken or grow rigid. PAH is one of the five groups of pulmonary hypertension, classified by the World Health Organization (WHO).
Request a Sample PDF Copy of This Report @ https://www.millioninsights.com/industry-reports/pulmonary-arterial-hypertension-pah-market/request-sample
Market Synopsis of Pulmonary Arterial Hypertension Market:
Globally the PAH market is segmented on the basis of Drug class, Surgery, and region. On the basis of Drug class, the global PAH market is classified into Endothelin Receptor Antagonists (ERAs) (Tracleer, Opsumit, Letairis)- These medications reverse the effect of endothelin, a substance in the walls of blood vessels that causes them to narrow; Prostacyclin and Prostacyclin Analogs- were the first medications approved by the U.S. FDA for the treatment of PAH. Phosphodiesterase-5 (PDE-5) V Inhibitors, Sildenafil, and Tadalafil- Revatio, Viagra, Cialis, etc. These drugs work by opening the blood vessels in the lungs to allow blood to flow easily. These drugs have superiority over existing therapy options with respect to the therapeutic efficacy, route of administration, and side-effects.
A new drug called Uptravi (selexipag), which is a selective IP prostacyclin receptor agonist, is expected to be launched in 2016 and is likely to drive growth of the prostacyclin and prostacyclin analogs market. The rising sales of these newly-approved therapeutic agents are likely to contribute to the overall revenue of the market.
Globally, regulatory bodies have granted an Orphan Drug Designation (ODD) status to all those drugs intended to diagnose and treat or cure a rare disease. In the U.S., the Orphan Drug Act (ODA) encourages pharmaceutical industries to develop orphan drugs by offering benefits such as tax credits, research grants, and orphan drug exclusivity of seven years. These benefits are escalating the development, manufacturing, and marketing of drugs intended to treat PAH, thereby driving market growth.
On the basis of surgeries, the global PAH market is classified into Atrial Septostomy- This is an open heart surgery; in which surgeon will create an opening between the upper left and right chambers of your heart to relieve the pressure on the right side of heart. Transplantation- Lung or heart-lung transplant might be an option especially for younger people who have idiopathic pulmonary arterial hypertension.
Geographically, PAH market is segmented into North America, Europe, Asia Pacific, Latin America, MEA, and Rest of the World. North America held the maximum share of market for PAH in terms of revenue in 2013, which is then followed by Europe. These two developed regions are expected to witness substantial growth during the forecast period, due to the recently approved PAH drugs in the market and the products that are anticipated to receive approval during the next few years. In the Asia Pacific region, Japan, China, India, Australia, and New Zealand exhibit immense opportunities for the companies operating in the PAH market.
View Full Table of Contents of This Report @ https://www.millioninsights.com/industry-reports/pulmonary-arterial-hypertension-pah-market
Table of Contents:-
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Pulmonary Arterial Hypertension: Market Variables, Trends & Scope
Chapter 4 Pulmonary Arterial Hypertension: Product Estimates & Trend Analysis
Chapter 5 Pulmonary Arterial Hypertension: Application Estimates & Trend Analysis
Chapter 6 Pulmonary Arterial Hypertension: End-use Estimates & Trend Analysis
Chapter 7 Pulmonary Arterial Hypertension: Industrial End-use Estimates & Trend Analysis
Chapter 8 Pulmonary Arterial Hypertension: Regional Estimates & Trend Analysis
Chapter 9 Competitive Landscape
Chapter 10 Pulmonary Arterial Hypertension: Manufacturers Company Profiles
Get in touch
At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.
The global pulmonary arterial hypertension (PAH) market size was valued at USD 5.0 billion in 2015 and is anticipated to reach USD 8.7 billion by 2025.
PAH occurs when the pulmonary arteries thicken or grow rigid.
These drugs have superiority over existing therapy options with respect to the therapeutic efficacy, route of administration, and side-effects.Download Free Sample Report @ https://www.millioninsights.com/industry-reports/pulmonary-arterial-hypertension-pah-market/request-sampleA new drug called Uptravi (selexipag), which is a selective IP prostacyclin receptor agonist, is expected to be launched in 2016 and is likely to drive growth of the prostacyclin and prostacyclin analogs market.
In the U.S., the Orphan Drug Act (ODA) encourages pharmaceutical industries to develop orphan drugs by offering benefits such as tax credits, research grants, and orphan drug exclusivity of seven years.
Transplantation- Lung or heart-lung transplant might be an option especially for younger people who have idiopathic pulmonary arterial hypertension.Geographically, PAH market is segmented into North America, Europe, Asia Pacific, Latin America, MEA, and Rest of the World.
North America held the maximum share of market for PAH in terms of revenue in 2013, which is then followed by Europe.
The ‘Pulmonary Arterial Hypertension (PAH)- Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of PAH in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
Also the Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Pulmonary Arterial Hypertension (PAH) from 2016 to 2027 segmented by seven major markets.Complete report on Global Pulmonary Arterial Hypertension (PAH) Market Size, Trends And Forecast Report 2014 – 2025 Enquire more@ https://franknraf.com/reports/global-pulmonary-arterial-hypertension-pah-market-size-trends-and-forecast-report-2014-2025/The Report research analysis also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered The United States EU5 (Germany, France, Italy, Spain and the United Kingdom) Japan Study Period: 2016-2027 Pulmonary Arterial Hypertension (PAH) - Disease Understanding and Treatment Algorithm.Get Sample copy of the report@ https://franknraf.com/sample-report/?rpt_id=6169The Pulmonary Arterial Hypertension (PAH) market report gives the thorough understanding of the Pulmonary Arterial Hypertension (PAH) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends.
The research analysis also provides treatment algorithms and treatment guidelines for Pulmonary Arterial Hypertension (PAH) in the US, Europe, and Japan.
Pulmonary Arterial Hypertension (PAH) Epidemiology The Pulmonary Arterial Hypertension (PAH) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries.
Also it helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.Pulmonary Arterial Hypertension (PAH) Drug Chapters This segment of the Pulmonary Arterial Hypertension (PAH) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
